Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Change in Acquisitions & Divestments (2022 - 2024)

Immuneering has reported Change in Acquisitions & Divestments over the past 3 years, most recently at $5.5 million for Q4 2024.

  • Quarterly results put Change in Acquisitions & Divestments at $5.5 million for Q4 2024, down 71.13% from a year ago — trailing twelve months through Dec 2024 was $31.9 million (down 38.95% YoY), and the annual figure for FY2024 was $31.9 million, down 38.95%.
  • Change in Acquisitions & Divestments for Q4 2024 was $5.5 million at Immuneering, up from $5.0 million in the prior quarter.
  • Over the last five years, Change in Acquisitions & Divestments for IMRX hit a ceiling of $32.3 million in Q2 2022 and a floor of $5.0 million in Q3 2023.
  • Median Change in Acquisitions & Divestments over the past 3 years was $19.0 million (2023), compared with a mean of $16.1 million.
  • Biggest five-year swings in Change in Acquisitions & Divestments: tumbled 74.03% in 2023 and later grew 12.79% in 2024.
  • Immuneering's Change in Acquisitions & Divestments stood at $20.6 million in 2022, then fell by 7.52% to $19.0 million in 2023, then plummeted by 71.13% to $5.5 million in 2024.
  • The last three reported values for Change in Acquisitions & Divestments were $5.5 million (Q4 2024), $5.0 million (Q2 2024), and $21.4 million (Q1 2024) per Business Quant data.